Bora Biologics has acquired Bora Pharmaceuticals for an undisclosed amount. This strategic transaction signifies a notable expansion for Bora Biologics within the biopharmaceutical sector.
Bora Pharmaceuticals is a premier international contract development and manufacturing organization (CDMO). It specializes in complex oral solid dose, liquids, semi-solids, ophthalmics, biologics, and sterile injectable products, offering services from early phase clinical to commercial manufacturing with comprehensive packaging capabilities for biopharma companies worldwide. The company operates ten state-of-the-art CGMP manufacturing facilities across Asia and North America, delivering to over 100 global markets. Bora Biologics, by its name, is understood to be focused on the biologics segment of the pharmaceutical industry.
This acquisition is strategically designed to bolster Bora Biologics' presence and capabilities in the expanding biopharmaceutical CDMO market. By integrating Bora Pharmaceuticals' extensive manufacturing infrastructure, global operational footprint, and diverse product expertise, Bora Biologics aims to significantly enhance its service portfolio, particularly in complex biologics and sterile injectables. The expected synergies include a more comprehensive offering for biopharma partners, streamlining development and manufacturing processes, and leveraging Bora Pharmaceuticals' established reputation for quality and international standards.
The combined entity is poised to offer an integrated suite of CDMO solutions, capitalizing on Bora Pharmaceuticals' global reach and operational excellence. This acquisition positions Bora Biologics to become a more robust and versatile partner in the global CDMO landscape, equipped with enhanced capacity and specialized expertise to address the evolving demands of the biopharmaceutical industry.